To determine whether CyPAllGlo results could be used to predict the efficacy of anti-platelet treatments, statistical analyses was employed to assess the association of drug efficacy and patient health information, including gender, age, CYP2C19 SNPs, metabolic phenotype, myocardial infarction, hypertension, diabetes, smoking history, preoperative/ postoperative platelet count, and blood levels of TG, LDL, and Creatinine. This evidence concerns the gene CYP2C19 and diabetes mellitus.